Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Eur J Surg Oncol. 2021 Jul;47(7):1535-1540. doi: 10.1016/j.ejso.2021.02.016. Epub 2021 Feb 17.
The effects of ligating the pulmonary vein first or pulmonary artery first during lobectomy on the long-term survival of patients with non-small cell lung cancer (NSCLC) remain controversial. We conducted the first systematic review and meta-analysis to determine the association between different sequences of vessel ligation during lobectomy and the prognosis of patients with NSCLC.
Literature retrieval was performed by systematically searching Embase, PubMed and Web of Science to identify relevant articles published from the inception of each database to November 2020. The overall survival (OS) and disease-free survival (DFS) of patients treated with vein-first ligation versus those treated with artery-first ligation during lobectomy were analyzed. A standard fixed-effect model test (Mantel-Haenszel method) was used to calculate pooled hazard ratios (HRs) and 95% confidence intervals (CIs). Heterogeneity was assessed using the Q-test and I-test. Sensitivity analysis was performed to further examine the stability of pooled HRs.
Five studies with a total of 1109 patients receiving lobectomy, including one randomized controlled trial and four retrospective studies, were included in this meta-analysis. The results showed that patients with vein-first ligation had a significantly better OS (HR 1.25, 95% CI 1.03-1.50; P = 0.02) and DFS (HR 1.54, 95% CI 1.16-2.04; P = 0.003) than those with artery-first ligation during lobectomy. Significant heterogeneity and publication bias were not observed during analysis.
Our meta-analysis indicates that vein-first ligation may improve the prognosis of NSCLC patients receiving lobectomy. Therefore, vein-first ligation is recommended during lobectomy for patients with non-small cell lung cancer whenever possible.
在肺叶切除术中,首先结扎肺静脉还是肺动脉对非小细胞肺癌(NSCLC)患者的长期生存影响仍存在争议。我们进行了首次系统评价和荟萃分析,以确定肺叶切除术中不同血管结扎顺序与 NSCLC 患者预后之间的关系。
通过系统检索 Embase、PubMed 和 Web of Science,从每个数据库的创建时间到 2020 年 11 月,确定相关文章。分析接受静脉优先结扎与动脉优先结扎的患者在肺叶切除术中的总生存(OS)和无病生存(DFS)。采用标准固定效应模型检验(Mantel-Haenszel 法)计算合并危险比(HR)和 95%置信区间(CI)。采用 Q 检验和 I 检验评估异质性。进行敏感性分析以进一步检查合并 HR 的稳定性。
本荟萃分析纳入了 5 项研究,共 1109 例接受肺叶切除术的患者,包括 1 项随机对照试验和 4 项回顾性研究。结果显示,与动脉优先结扎相比,静脉优先结扎的患者 OS(HR 1.25,95%CI 1.03-1.50;P=0.02)和 DFS(HR 1.54,95%CI 1.16-2.04;P=0.003)显著改善。分析过程中未观察到显著的异质性和发表偏倚。
本荟萃分析表明,静脉优先结扎可能改善接受肺叶切除术的 NSCLC 患者的预后。因此,在可行的情况下,建议在肺叶切除术中对非小细胞肺癌患者进行静脉优先结扎。